Ghent University Academic Bibliography

Advanced

Adjuvant or neoadjuvant chemotherapy in minimal N2 stage IIIA nonsmall cell lung cancer

SOFIE DE CRAENE UGent, Veerle Surmont UGent and Jan Van Meerbeeck UGent (2010) CURRENT OPINION IN ONCOLOGY. 22(2). p.102-111
abstract
Purpose of review: In the last decade, numerous randomized trials have evaluated the benefit of (neo-)adjuvant chemotherapy in nonsmall cell lung cancer. This article will review the recent data on perioperative chemotherapy in stage III A-N2 nonsmall cell lung cancer and future research opportunities are presented. Recent findings: Four retrospective series, two phase 2 and four phase 3 trials in the neoadjuvant setting and one retrospective series, two phase 2 trials and two phase 3 trials in the adjuvant setting are retrieved and discussed. Summary: The available evidence does not allow to change the current recommendation regarding the management of patients presenting with biopsy-proven clinical stage IIIA-N2 nonsmall cell lung cancer: their preferred treatment is chemoradiotherapy. Surgery with neoadjuvant or adjuvant chemotherapy is not proven superior to radiotherapy. The patient occasionally presenting with unforeseen pN2 despite adequate preoperative mediastinal staging should be offered adjuvant cisplatin-based chemotherapy and possibly postoperative radiotherapy.
Please use this url to cite or link to this publication:
author
organization
year
type
journalArticle (review)
publication status
published
subject
keyword
combined modality, chemotherapy, radiotherapy, stage IIIA-N2, surgery, POSITRON-EMISSION-TOMOGRAPHY, INDUCTION CHEMOTHERAPY, NEEDLE-ASPIRATION, PHASE-III, TRIAL, THERAPY, SURGERY, CHEMORADIOTHERAPY, CARBOPLATIN, EXPERIENCE
journal title
CURRENT OPINION IN ONCOLOGY
Curr. Opin. Oncol.
volume
22
issue
2
pages
102 - 111
Web of Science type
Review
Web of Science id
000275198100005
JCR category
ONCOLOGY
JCR impact factor
4.386 (2010)
JCR rank
41/181 (2010)
JCR quartile
1 (2010)
ISSN
1040-8746
DOI
10.1097/CCO.0b013e328335c076
language
English
UGent publication?
yes
classification
A1
copyright statement
I have transferred the copyright for this publication to the publisher
id
923187
handle
http://hdl.handle.net/1854/LU-923187
date created
2010-04-12 11:22:08
date last changed
2011-07-08 15:09:42
@article{923187,
  abstract     = {Purpose of review: In the last decade, numerous randomized trials have evaluated the benefit of (neo-)adjuvant chemotherapy in nonsmall cell lung cancer. This article will review the recent data on perioperative chemotherapy in stage III A-N2 nonsmall cell lung cancer and future research opportunities are presented.
Recent findings: Four retrospective series, two phase 2 and four phase 3 trials in the neoadjuvant setting and one retrospective series, two phase 2 trials and two phase 3 trials in the adjuvant setting are retrieved and discussed.
Summary: The available evidence does not allow to change the current recommendation regarding the management of patients presenting with biopsy-proven clinical stage IIIA-N2 nonsmall cell lung cancer: their preferred treatment is chemoradiotherapy. Surgery with neoadjuvant or adjuvant chemotherapy is not proven superior to radiotherapy. The patient occasionally presenting with unforeseen pN2 despite adequate preoperative mediastinal staging should be offered adjuvant cisplatin-based chemotherapy and possibly postoperative radiotherapy.},
  author       = {DE CRAENE, SOFIE and Surmont, Veerle and Van Meerbeeck, Jan},
  issn         = {1040-8746},
  journal      = {CURRENT OPINION IN ONCOLOGY},
  keyword      = {combined modality,chemotherapy,radiotherapy,stage IIIA-N2,surgery,POSITRON-EMISSION-TOMOGRAPHY,INDUCTION CHEMOTHERAPY,NEEDLE-ASPIRATION,PHASE-III,TRIAL,THERAPY,SURGERY,CHEMORADIOTHERAPY,CARBOPLATIN,EXPERIENCE},
  language     = {eng},
  number       = {2},
  pages        = {102--111},
  title        = {Adjuvant or neoadjuvant chemotherapy in minimal N2 stage IIIA nonsmall cell lung cancer},
  url          = {http://dx.doi.org/10.1097/CCO.0b013e328335c076},
  volume       = {22},
  year         = {2010},
}

Chicago
DE CRAENE, SOFIE, VEERLE SURMONT, and Jan Van Meerbeeck. 2010. “Adjuvant or Neoadjuvant Chemotherapy in Minimal N2 Stage IIIA Nonsmall Cell Lung Cancer.” Current Opinion in Oncology 22 (2): 102–111.
APA
DE CRAENE, S., SURMONT, V., & Van Meerbeeck, J. (2010). Adjuvant or neoadjuvant chemotherapy in minimal N2 stage IIIA nonsmall cell lung cancer. CURRENT OPINION IN ONCOLOGY, 22(2), 102–111.
Vancouver
1.
DE CRAENE S, SURMONT V, Van Meerbeeck J. Adjuvant or neoadjuvant chemotherapy in minimal N2 stage IIIA nonsmall cell lung cancer. CURRENT OPINION IN ONCOLOGY. 2010;22(2):102–11.
MLA
DE CRAENE, SOFIE, VEERLE SURMONT, and Jan Van Meerbeeck. “Adjuvant or Neoadjuvant Chemotherapy in Minimal N2 Stage IIIA Nonsmall Cell Lung Cancer.” CURRENT OPINION IN ONCOLOGY 22.2 (2010): 102–111. Print.